arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cocrystal Pharma, Inc.

COCP
$1.17 ▼ -0.05 (-3.70%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cocrystal Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $16.1M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -240.9%
FCF / Share $-0.18
Trailing P/E
Price / Book 15.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$105.00K
↓ -53.3%
Net Income Profit after all expenses
$-2.30M
— +0.1%
Operating Margin Operating profit as % of sales
-287.5%
↑ +32.4%
FCF / Share Free cash flow per share
$-0.18
↓ -7.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
6
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 65 quarters